The battle against breast cancer is something everyone needs to participate in one way or another. It’s estimated that 1 in 8 women in America will be diagnosed with breast cancer before they die. It is one of the most lethal cancers among women. Especially in women over the age of 50. Hundreds of thousands of women die each year due to this deadly illness in the United States alone. Though predominantly found in women breast cancer does affect men.
Breast cancer treatments have come a long through the years. The most common treatments are radiation, hormone therapy, and surgery. Treatment will differ depending on the patient of course. Surgery is usually the first step in treatment. Though there have been many medical breakthroughs regarding this subject there is to a lot more work to do and much more to learn about this terrible form of cancer.
Thankfully, companies like Tempus exist. The anti-cancer startup has joined forces with the University of Chicago Medicine. Tempus will analyze and sequence the molecular data of nearly 1,000 female patients suffering from breast cancer, in the hopes of aiding doctors in deciding on the right treatment method for an individual patient. To this point, doctors have mostly been taking shots in the dark when it comes to choosing the treatment method with the highest chance of success. If all works out well this could largely impact the way doctors will treat breast cancer around the world in years to come and learn more about Eric.
About Eric Lefkofsky
Eric Lefkosky is an american entrepreneur who has founded numerous startups throughout his successful career. Those of which include companies such as Lightbank, Groupon and ECHO. Lefkosky is also CEO and co-founder of cancer fighting technology company Tempus. In 2006 he founded the Lefkosky Foundation, a non-profit that has provided funding to several charitable organizations and more information click here.